To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Recruiting now · Phase 2

Conditions studied: Breast Cancer

In brief

The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.

Key facts

Study ID
NCT07368998
Run by
Hoffmann-La Roche
People needed
80
Starts
2026-02-18
Expected to finish
2031-10-31
Last updated by the study team
2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.